Ultrasonography of the prostate

• US 6,428,479 B1
• Filed: 06/19/2000
• Issued: 08/06/2002
• Est. Priority Date: 12/17/1997
• Status: Expired due to Fees

• Current Assignee: GE Healthcare As (GE Healthcare Technologies, Inc.)
• Original Assignee: Nycomed Imaging AS (GE Healthcare Technologies, Inc.)
• Inventors: Eriksen, Morten, Tornes, Audun, Aksnes, Anne Kirsti, Hagen, Else Kruger
• Primary Examiner(s): Jaworski, Francis J.
• Application Number:
  US09/597,406
• Time in Patent Office: 778 Days
• Field of Search: 600/437, 600/439, 600/443, 600/447, 600/454-456, 600/459, 600/462-463, 601/2-3, 424/9, 424/52
• US Class Current: 600/458
• CPC Class Codes: A61B 8/06 Measuring blood flow measuring volume flow in general G01F, e.g. G01F1/66, G01F1/72; measuring speed of fluids in general G01P5/00
• CPC Class Codes: A61B 8/12 in body cavities or body tracts, e.g. by using catheters catheters per se A61M25/00
• CPC Class Codes: A61B 8/481 involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream analysis of echo signal exploiting properties of a contrast enhancer in devices for short-range imaging with acoustic waves G01S7/52039
• CPC Class Codes: A61B 8/543 involving acquisition triggered by a physiological signal

Abstract

Prostate abnormalities such as cancer may be detected by ultrasonic determination of the in-flow kinetics of contrast agent-containing blood in the prostate and/or by observation of disease-related asymmetries in the spoke-like vascular pattern of the prostate.

Claims

1. A method for diagnosing prostate disease in a subject which comprises:

intravascularly administering an ultrasound contrast agent to said subject, ultrasonically determining flow and/or volume kinetic data in respect of contrast agent-containing blood flowing into and traversing at least a part of the prostate gland of said subject, and analysing said kinetic data to identifying disease-induced changes in vascularity within the prostate gland.

2. A method as claimed in claim 1 wherein the ultrasound contrast agent is administered as a bolus and said kinetic data is determined by monitoring temporal development of contrast effect caused by arrival of said bolus in different regions of prostate tissue.

3. A method as claimed in claim 1 wherein ultrasound image data in respect of inward flow of contrast agent-enhanced blood within the spoke like vascular pattern of the prostate are generated.

4. A method as claimed in claim 1 wherein perfusion-weighted ultrasound image data are generated using power Doppler imaging.

5. A method as claimed in claim 1 wherein ultrasound image data are processed to generate waveforms representative of arterial pulsatility and said waveforms are analysed for variations characteristic of local aberrations in tissue perfusion and/or compliance within the prostate.

6. A method as claimed in claim 5 wherein the ultrasound image data are generated by power Doppler imaging.

7. A method as claimed in claim 6 wherein the ultrasound image data are processed by high-pass filtering at a threshold such that a pulsatile pattern is generated as arterial blood velocity varies above and below said threshold.

8. A method as claimed in claim 5 wherein the ultrasound image data are processed with respect to a frequency and phase reference.

9. A method as claimed in claim 8 wherein said frequency and phase reference is a cardiac-synchronous signal.

10. A method as claimed in claim 8 wherein the ultrasound image data are processed to generate phase information, and phase shift detection is employed to identify potential local aberrations in tissue perfusion and/or compliance within the prostate.

11. A method as claimed in claim 8 wherein the ultrasound image data are generated by power Doppler imaging, harmonic imaging or pulse inversion imaging.

12. A method as claimed in claim 1 which is combined with three dimensional acquisition and reconstruction of ultrasound image data.

13. A method as claimed in claim 1 wherein the ultrasound contrast agent comprises gas microbubbles stabilised by amphiphilic material consisting essentially of phospholipid predominantly comprising molecules which individually have an overall net charge.

14. A method as claimed in claim 13 wherein the amphiphilic material comprises one or more phosphatidylserines constituting at least 70% of the phospholipid content and in which the gas content of the microbubbles comprises sulphur hexafluoride or a C_1-6 fluorinated hydrocarbon.

15. A method as claimed in claim 14 wherein the gas content of the microbubbles comprises perfluoropropane, perfluorobutane and/or perfluoropentane.

16. A method as claimed in claim 1 wherein the ultrasound image data are generated using a transrectal transducer.

17. A method as claimed in claim 1 wherein said identification of disease-induced changes in vascularity within the prostate is used in diagnosis of prostate abnormalities, identification of sites in need of biopsy, evaluation of extent or state of disease, characterisation of identified lesions, consideration of best or most appropriate form of therapy, evaluation of prognosis, evaluation of efficacy of therapy, evaluation of progression or regression of disease, or identification of conditions associated with aberrant vascularisation resulting from inflammation, hyperplasia or tumour-induced angiogenesis.

18. A method for diagnosing prostate disease in a subject which comprises administering an ultrasound contrast agent to the vascular system of said subject, ultrasonically imaging at least a part of the prostate gland of said subject and analysing the ultrasound image data so obtained for disease-related asymmetries in the spoke-like vascular pattern of the prostate.